AC Immune (ACIU) Retained Earnings (2015 - 2025)
AC Immune (ACIU) reported Retained Earnings of -$549.3 million for Q4 2025, down 30.67% year-over-year from -$792.3 million in Q4 2024, and down 4.68% on a QoQ basis from -$524.7 million in Q3 2025.
AC Immune (ACIU) has 11 years of Retained Earnings data on file, last reported at -$549.3 million in Q4 2025.
- Quarterly Retained Earnings fell 30.67% year-over-year to -$549.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$549.3 million (down 30.67% YoY) and the FY2025 annual result came in at -$529.5 million, down 25.97% from the prior year.
- Retained Earnings retreated to -$549.3 million in Q4 2025 per ACIU's latest filing, from -$524.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$236.9 million in Q1 2022 and bottomed at -$356.5 billion in Q4 2023.
- The 5-year median for Retained Earnings is -$411.5 million (2024), against an average of -$56.3 billion.
- The widest annual swing landed in 2021, when Retained Earnings sank 193052.78%; it then jumped 99.88% in 2024.
- Tracing ACIU's Retained Earnings over 5 years: stood at -$217.9 billion in 2021, then surged by 99.87% to -$274.1 million in 2022, then slumped by 129971.79% to -$356.5 billion in 2023, then jumped by 99.88% to -$420.4 million in 2024, then slumped by 30.67% to -$549.3 million in 2025.
- Per Business Quant, the three latest ACIU Retained Earnings figures stand at -$549.3 million (Q4 2025), -$524.7 million (Q3 2025), and -$491.6 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -549.29 Mn |
| Sep 30, 2025 | -524.73 Mn |
| Jun 30, 2025 | -491.56 Mn |
| Mar 31, 2025 | -429.56 Mn |
| Dec 31, 2024 | -420.35 Mn |
| Sep 30, 2024 | -402.75 Mn |
| Jun 30, 2024 | -392.12 Mn |
| Mar 31, 2024 | -381.01 Mn |
| Dec 31, 2023 | -356.47 Bn |
| Sep 30, 2023 | -351.52 Mn |
| Jun 30, 2023 | -329.27 Mn |
| Mar 31, 2023 | -302.84 Mn |
| Dec 31, 2022 | -274.05 Mn |
| Sep 30, 2022 | -251.61 Mn |
| Jun 30, 2022 | -238.98 Mn |
| Mar 31, 2022 | -236.91 Mn |
| Dec 31, 2021 | -217.92 Bn |
| Sep 30, 2021 | -197.86 Bn |
| Jun 30, 2021 | -183.22 Bn |
| Mar 31, 2021 | -164.55 Bn |
| Dec 31, 2020 | -146.95 Mn |
| Sep 30, 2020 | -124.97 Mn |
| Jun 30, 2020 | -100.89 Mn |
| Mar 31, 2020 | -85.19 Mn |
| Dec 31, 2019 | -76.31 Mn |
| Sep 30, 2019 | -56.36 Mn |
| Jun 30, 2019 | -73,970.33 |
| Mar 31, 2019 | -58.00 Mn |
| Dec 31, 2018 | -122.47 Mn |
| Dec 31, 2017 | -73.59 Mn |
| Mar 31, 2017 | -56.05 Mn |
| Dec 31, 2016 | -46.92 Mn |
| Sep 30, 2016 | -43.99 Mn |
| Dec 31, 2015 | -40.81 Mn |